We now demonstrate for the first time that the tyrosine kinase inhibitor Foretinib effectively inhibits TAM family members in glioblastoma, and most robustly MerTK, leading to an inhibition of the critical phenotypes of glioblastoma and a dramatic tumor response in in vivo mouse models of disease. This evidence concerns the gene MERTK and glioblastoma.